Mitsubishi UFJ Securities Holdings Co. Ltd. cut its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 44.6% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,860 shares of the biopharmaceutical company’s stock after selling 1,500 shares during the period. Mitsubishi UFJ Securities Holdings Co. Ltd.’s holdings in Gilead Sciences were worth $132,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Wealthsource Partners LLC purchased a new position in shares of Gilead Sciences in the second quarter valued at approximately $206,000. Sequoia Financial Advisors LLC lifted its stake in Gilead Sciences by 1.0% in the second quarter. Sequoia Financial Advisors LLC now owns 92,101 shares of the biopharmaceutical company’s stock worth $6,524,000 after acquiring an additional 870 shares during the last quarter. BTG Pactual Global Asset Management Ltd lifted its stake in Gilead Sciences by 12.7% in the second quarter. BTG Pactual Global Asset Management Ltd now owns 9,525 shares of the biopharmaceutical company’s stock worth $675,000 after acquiring an additional 1,071 shares during the last quarter. Lcnb Corp purchased a new position in Gilead Sciences in the second quarter worth approximately $310,000. Finally, Senvest Management LLC purchased a new position in Gilead Sciences in the second quarter worth approximately $4,959,000. Institutional investors and hedge funds own 78.01% of the company’s stock.
A number of research analysts recently issued reports on the stock. ValuEngine downgraded shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Monday, August 20th. BidaskClub downgraded shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Saturday, August 18th. Mizuho reiterated a “buy” rating and issued a $94.00 price target on shares of Gilead Sciences in a research note on Friday, August 10th. Morgan Stanley lifted their price target on shares of Gilead Sciences from $81.00 to $85.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 26th. Finally, Wells Fargo & Co lifted their price target on shares of Gilead Sciences from $89.00 to $95.00 and gave the stock an “outperform” rating in a research note on Thursday, July 26th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have issued a buy rating and two have given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $88.30.
Shares of NASDAQ:GILD opened at $72.88 on Friday. The company has a market cap of $96.62 billion, a PE ratio of 8.51, a P/E/G ratio of -5.68 and a beta of 1.02. The company has a quick ratio of 2.92, a current ratio of 3.00 and a debt-to-equity ratio of 1.23. Gilead Sciences, Inc. has a twelve month low of $64.27 and a twelve month high of $89.54.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Wednesday, July 25th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, topping the consensus estimate of $1.56 by $0.35. The business had revenue of $5.65 billion during the quarter, compared to the consensus estimate of $5.20 billion. Gilead Sciences had a net margin of 9.52% and a return on equity of 41.57%. The company’s revenue was down 20.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.56 EPS. equities research analysts forecast that Gilead Sciences, Inc. will post 6.56 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 27th. Stockholders of record on Friday, September 14th will be given a dividend of $0.57 per share. The ex-dividend date of this dividend is Thursday, September 13th. This represents a $2.28 annualized dividend and a dividend yield of 3.13%. Gilead Sciences’s dividend payout ratio is presently 26.64%.
In other news, Director John C. Martin sold 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 1st. The shares were sold at an average price of $77.85, for a total transaction of $3,892,500.00. Following the completion of the sale, the director now owns 3,067,762 shares in the company, valued at approximately $238,825,271.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold a total of 150,000 shares of company stock valued at $11,141,000 in the last 90 days. Insiders own 1.30% of the company’s stock.
Gilead Sciences Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Featured Story: NASDAQ Stock Market Explained
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.